Role of CVBF
ID-EPTRI project, coordinated by CVBF-TEDDY, has been submitted on March 29th, 2017, within the INFRADEV-01-2017 single-stage call for proposals with the aim to create the framework for a new Research Infrastructure (RI) intended to enhance technology-driven paediatric research in discovery and early development phases to be translated into clinical research and paediatric use of medicines.
The project arises from the need to find answers to the serious lack of medicines for children in EU and worldwide and to propose development models for paediatric medicines that integrates technology-driven aspects with clinical trials. The interest for Paediatrics was indeed mentioned in the ESFRI Road Map 2016 (http://www.esfri.eu/sites/default/files/20160309_ROADMAP_browsable.pdf) where it was recognised that a similar RI should be included into the landscape of the research in Europe.
EPTRI will be a complementary RI in the context of the existing RIs covering the current gaps in paediatric medicines. The new RI will represent a “one-stop-shop” and a paediatric common service with three already established Research Infrastructures (BBMRI, EATRIS, ECRIN) to harness efficiency and delivery of paediatric research activities and services strengthening collaboration within the scientific paediatric community.
The final result of the project will be the Conceptual Design Report to realize EPTRI, the European Paediatric Translational Research Infrastructure, describing the scientific and technical requirements as well as the key components of the new RI.
European Union’s Horizon 2020 programme
3.00 million euro
3.00 million euro
(1) Consorzio per Valutazioni Biologiche e Farmacologiche (CVBF), Italy; (2) Fondazione PENTA – For the treatment and care of children with HIV – ONLUS (PENTA), Italy; (3) European Infrastructure for Translational Medicine (EATRIS ERIC), The Netherlands; (4) University College London (UCL), United Kingdom; (5) ATHENA Research and innovation center in information communication & knowledge technologies (ATHENA), Greece; (6) Biobanks and BioMolecular resources Research Infrastructure Consortium (BBMRI), Austria; (7) The Cyprus foundation for muscular dystrophy research (CING), Cyprus; (8) Assistance Publique – Hopitaux de Paris (AP-HP), France; (9) Stichting Katholieke Universiteit (RUN-MC), The Netherlands; (10) The University of Liverpool (ULIV), United Kingdom; (11) Fundatia Apelul Ingerului Romanianangel Appeal (RAA), Romania; (12) Instytut Pomnik Centrum Zdrowia Dziecka (IPCZD), Poland; (13) Erasmus Universitair Medisch Centrum Rotterdam (EMC), The Netherlands; (14) Ospedale Pediatrico Bambino Gesù (OPBG), Italy; (15) Fyziologicky Ustav Akademie ved Ceske Republiky Verejna Vyzkumna Instituce (IPHYS), Czech Republic; (16) Fundacio Sant Joan de Deu (FSJD), Spain; (17) Nizhegorodskiy Gosudarstvenniy Universitet Im N.I. Lobachevskogo (UNN), Russia; (18) Servicio Madrileno de Salud (SERMAS-HULP), Spain; (19) European Clinical Research Infrastructure Network (ECRIN), France; (20) Qendra Spitalore Universitare Nene Tereza Tirane (UHCT), Albania; (21) TECHNION – Israel Institute of Technology (TECHNION), Israel; (22) Tartu Ulikool (UTARTU), Estonia; (23) Universitatsklinikum Erlangen (UKER), Germany; (24) Swiss Clinical Trial Organisation Verein (SwissPedNet), Switzerland; (25) State “Institute of Pediatrics Obstetrics and Gynecology National Academy of Medical Sciences of Ukraine” (UKR), Ukraine; (26) Vastra Gotaland Lans Landsting (VGR), Sweden.